Form 4: Twist Bioscience Director Robert Chess Executes Stock Transactions Under 10b5-1 Plan

Director Robert Chess of Twist Bioscience Corp. executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Summary

• Robert Chess, a director at Twist Bioscience Corp., engaged in several transactions involving the company's stock on November 11, 2024.
• These transactions included the exercise of stock options to acquire 3,600 shares at $8.82 per share and the subsequent sale of 2,324 shares at an average price of $46.9894 and 1,276 shares at an average price of $47.755.
• The sales were executed under a pre-existing Rule 10b5-1 trading plan adopted on August 12, 2024.
• Following these transactions, Mr. Chess directly owns 21,641 shares and indirectly owns 42,528 shares through the Chess 1997 Trust.
• He also holds options for 3,504 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not indicate any significant positive or negative outlook for the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common practice for insiders to avoid accusations of trading on non-public information.

Negatives

• The sale of shares by a director could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• The market may react to insider sales, potentially causing short-term price fluctuations.
• The reliance on a 10b5-1 plan does not eliminate the risk of negative sentiment if the sales are perceived as a lack of confidence in the company's future.

Industry Context

This is a routine filing related to insider trading activity. It is common for directors and officers to use 10b5-1 plans to manage their stock transactions.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice among public company executives and directors to manage their stock transactions and avoid accusations of insider trading.
• The reported transactions are similar to those seen in other biotechnology companies where executives hold stock options and periodically sell shares for personal financial management.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, potentially causing short-term price fluctuations, but are not expected to have a significant long-term effect.

Key Dates

Keywords

Twist Bioscience, Robert Chess, insider trading, Form 4, stock options, 10b5-1 plan, share sales, director